Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S, Gentile M, Sacchi S, Marcheselli R, Corso A, Cocito F, Musto P, Guarini A, Minoia C, Vincelli I, Ria R, Rivolti E, Mele G, Bari A, Mazzone C, Badiali S, Marcheselli L, Palumbo A, Morabito F. Pozzi S, et al. Among authors: corso a. Leuk Lymphoma. 2017 Mar;58(3):552-559. doi: 10.1080/10428194.2016.1205741. Epub 2016 Jul 21. Leuk Lymphoma. 2017. PMID: 27442600 Clinical Trial.
Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
Mangiacavalli S, Pochintesta L, Ravelli E, Baldini L, Ferretti VV, La Targia ML, Farina L, Cocito F, Cairoli R, Montefusco V, Corso A. Mangiacavalli S, et al. Among authors: corso a. Leuk Lymphoma. 2015 Jun;56(6):1901-2. doi: 10.3109/10428194.2014.979414. Epub 2015 Jan 14. Leuk Lymphoma. 2015. PMID: 25347423 Clinical Trial. No abstract available.
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Mangiacavalli S, Albani G, Caravita T, Cocito F, Pascutto C, Zappasodi P, Bringhen S, Palumbo A, Cazzola M, Corso A. Mangiacavalli S, et al. Among authors: corso a. Leuk Lymphoma. 2012 Mar;53(3):514-5. doi: 10.3109/10428194.2011.600487. Epub 2011 Dec 5. Leuk Lymphoma. 2012. PMID: 22141736 Clinical Trial. No abstract available.
Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
Cocito F, Mangiacavalli S, Bernasconi P, Colombo AA, Caldera D, Cartia CS, Ganzetti M, Troletti D, Cazzola M, Corso A. Cocito F, et al. Among authors: corso a. Leuk Lymphoma. 2017 Nov;58(11):2770-2771. doi: 10.1080/10428194.2017.1300890. Epub 2017 Mar 13. Leuk Lymphoma. 2017. PMID: 28287281 No abstract available.
The advantages of switch to subcutaneous bortezomib in the real life.
Mangiacavalli S, Cocito F, Ferretti VV, Ganzetti M, Cartia CS, Corso A. Mangiacavalli S, et al. Among authors: corso a. Leuk Lymphoma. 2018 Jun;59(6):1505-1507. doi: 10.1080/10428194.2017.1382695. Epub 2017 Oct 5. Leuk Lymphoma. 2018. PMID: 28980500 No abstract available.
459 results